Post-op radiation does not improve survival after complete thymoma resection
Article Thumbnail ImageDecember 2, 2009 -- NEW YORK (Reuters Health), Dec 2 - Postoperative radiotherapy after complete thymoma resection "has little impact on survival," according to a report from Japan in the December 1 issue of Cancer.
Member Sign In:
  MemberID or E-mail Address:
  Password:
(?)

New AuntMinnie.com Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • OnLine CMe/CE
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • This finding, the authors say, is at least partly because even without radiotherapy, their early-stage thymoma patients had good long-term outcomes after complete resection, "which made it difficult to demonstrate that postoperative radiotherapy had a further benefit on survival."

    Dr. Tomoki Utsumi from Osaka University Graduate School of Medicine and colleagues investigated the impact of postoperative radiation on survival in 324 patients who underwent complete resection of a thymoma between 1970 and 2005.

    The actuarial 10- and 20-year disease-specific survival rates were 92.8% and 83.5%, respectively, for patients who received postoperative radiation, the authors report, compared with 94.4% and 94.4%, respectively, for those treated without radiation therapy (P=0.2208).

    Actuarial overall survival rates at 10 and 20 years were 80.7% and 56.5% for those who received postoperative radiation therapy and 86.2% and 40.4% for those who did not (P=0.0640).

    In addition, radiation therapy did not impact survival in subgroups of patients stratified by disease stage or WHO cell type, the researchers note.

    "Surgical resection alone is sufficient for thymoma patients with Masaoka stage I and II and those with WHO cell types A, AB, and B1," Dr. Utsumi and associates write. In these groups, 10-year disease-specific survival was 100% without radiation.

    "Furthermore," they conclude, "an optimal treatment strategy should be established for patients with Masaoka stage III/IV and WHO cell type B2/B3 thymomas," whose survival - while unaffected by radiation therapy -- is reduced compared to patients with earlier stage disease.

    Cancer 2009;115:5413-5420.

    Last Updated: 2009-12-01 17:45:49 -0400 (Reuters Health)

    Related Reading

    Surgeons question need for adjuvant radiotherapy for thymoma, February 3, 2003

    Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.


    || About || Advertising || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2013 || Education || Equipment Classifieds || Facebook || Forums || Home || Links || Marketplace || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2012 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2013 AuntMinnie.com. All Rights Reserved.